Article

Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein

Department of Structural Biology and Bioinformatics, Centre Médical Universitaire, 1 rue Michel Servet, 1211 Geneva 4, Switzerland.
Bioconjugate Chemistry (Impact Factor: 4.82). 03/2008; 19(2):480-9. DOI: 10.1021/bc7003044
Source: PubMed

ABSTRACT New HIV prevention methods are needed, and among those currently being explored are "microbicides", substances applied topically to prevent HIV acquisition during sexual intercourse. The chemokine analogue PSC-RANTES (N(alpha)(n-nonanoyl)-des-Ser(1)-[ L-thioprolyl(2), L-cyclohexylglycyl(3)]-RANTES(4-68)) is a highly potent HIV entry inhibitor which has shown promising efficacy in its initial evaluation as a candidate microbicide. However, a way must be found to produce the molecule by cheaper means than total chemical synthesis. Since the only noncoded structures are located at the N-terminus, a possible solution would be to produce a protein fragment representing all but the N-terminal region using low-cost recombinant production methods and then to attach, site specifically, a short synthetic fragment containing the noncoded N-terminal structures. Here, we describe the evaluation of a range of different conjugation chemistries in order to identify those with potential for development as economical routes to production of a PSC-RANTES analogue with antiviral activity as close as possible to that of the parent protein. The strategies tested involved linkage through oxime, hydrazone/hydrazide, and Psi[CH2-NH] bonds, as well as through a peptide bond obtained either by a thiazolidine rearrangement or by direct alpha-amino acylation of a protein fragment in which 4 of the 5 lysine residues of the native sequence were replaced by arginine (the fifth lysine is essential for activity). Where conjugation involved replacement of one or more residues with a linker moiety, the point in the main chain at which the linker was introduced was varied. The resulting panel of 22 PSC-RANTES analogues was evaluated for anti-HIV activity in an entry inhibition assay. The [Arg (25,45,56,57)] PSC-RANTES analogue has comparable potency to PSC-RANTES, and one of the oxime linked analogues, 4L-57, has potency only 5-fold lower, with scope for improvement. Both represent promising leads for development as microbicide compounds that could be produced at low cost via semisynthesis.

0 Bookmarks
 · 
108 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Series of new organotin(IV) complexes of the types R2SnL, R is Me (1), Ph (2), o-Cl–C6H4CH2 (3); and [R3SnL]∞, R = n-Bu (4) (H2L = 2-hydroxy-1-naphthaldehyde 5-chloro-2-hydroxybenzoylhydrazone) have been synthesized and structurally characterized by means of elemental analysis, FT-IR, UV–vis spectroscopy, NMR (1H, 13C and 119Sn) spectra and X-ray single crystal diffraction analyses. Structural analyses reveal that complexes 1–3 show similar monomeric structure, in which the tin center is coordinated with the enolic tridentate ligand (L) in the ONO chelate mode and exhibits five-coordinated trigonal bipyramidal geometry. Unexpectedly, complex 4 presents as a rare one-dimensional chain polymeric structure, in which the coordination of Sn is also five-coordinated trigonal bipyramidal geometry and the segment of tri-n-butyltin is bridged by the de-protonated phenolate O atom and the carbonyl O atom from the non-enolic Schiff base ligand. All compounds exhibit good in vitro antitumor activity toward human colon cancer cells (HCT-8), lung cancer cells (A549) and human promyelocyticfina leukemic cells (HL-60). The results indicate that both alkyl groups bound with tin centers and the structural of organotin compounds have significant effect on their in vitro antitumor activities. Among them, the polymeric tri-n-butyltin Schiff base complex 4 is the most active one, and the complex 3 shows high selectivity on the tumor cells HCT-8 and HL-60. For all of the title compounds, there was a good dose–effect relationship.
    Journal of Organometallic Chemistry 01/2013; 724:23–31. DOI:10.1016/j.jorganchem.2012.10.031 · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reactions of pyruvic acid hydrazone series [pyruvic acid thiophenecarbonyl hydrazone (L1), pyruvic acid 4-hydroxybenzoylhydrazone (L2), pyruvic acid salicyloylhydrazone (L3), pyruvic acid benzoylhydrazone (L4)], or salicylaldehyde hydrazone Schiff base ligand [salicylaldehyde isonicotinoylhydrazone (L5)] with different alkyltin salts result in six new organotin(IV) compounds, {(n-Bu)2Sn[2-SC4H3CON2C(CH3)CO2](HOC3H7-i)}2 (1), [{(n-Bu)2SnCl(O)(n-Bu)2 Sn(O)[C6H4CON2C(CH3)CO2]Sn(n-Bu)2(HOCH3)}2]∞ (2), {(o-ClBz)2Sn[4-HOC6H4CON2C(CH3) CO2] (HOC2H5)}2 (3), {(n-C8H17)2Sn[2-HOC6H4CON2C(CH3)CO2](H2O)}2 (4), {(n-Bu)2Sn[C6H5 CON2C(CH3)CO2][HOSn(n-Bu)3]}2 (5), and {[(n-C4H9)SnCl2]−[4-NHC5H4CON2CH (C6H4O-2)]+ (6), which have been characterized by single crystal X-ray diffraction, elemental analysis, IR, 1H and 119Sn NMR. In compounds 1, 3, 4, weak-bridged dimers are found, in which the two tin atoms are linked by a pair of monodentate CO2- bridges. Each pyruvic acid hydrazone ligand serves as an enolic tridentatic ligand. Compound 2 contains dimeric units of {Sn6(L2)2(n-Bu)6(HOCH3)2} that are further connected by two pairs of monodentate CO2- bridges into an 1D weak-bridged polymeric chain, in which there also exists a fascinating dichlorodistannoxane ladder structure. Studies show that the bulk and steric hindrance of the alkyl groups and the coordinated solvent molecule bonding to Sn center have little effect on the geometry of the weak-bridge for compounds 1–4. A similar weak-bridged dimeric structure is also found in compound 5; in this case, however, there is no coordinated solvent molecule and the corresponding coordination site is replaced by the trialkyltin hydroxide. Compound 6 exhibits a rare 1D supermolecular chain constructed from the zwitterionic {Sn(L5)(n-Bu)Cl2} units connected by the intermolecular N–H⋯Cl hydrogen bonds. The thermal stability of compound 1 was also studied.
    Journal of Organometallic Chemistry 03/2010; 695(5):653-662. DOI:10.1016/j.jorganchem.2009.11.035 · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to highlight potential therapeutics derived from peptides and proteins that show particular promise in HIV treatment. Molecules that act on CCR5, CXCR4 or on both receptors will be discussed herein.
    Experimental Biology and Medicine 05/2013; 238(5):442-9. DOI:10.1177/1535370213480696 · 2.23 Impact Factor